ProCE Banner Activity

DRIVE-FORWARD: Durable Virologic Efficacy With Doravirine Plus NRTIs vs Darunavir/Ritonavir Plus NRTIs Through Week 96 in ART-Naive Patients

Capsule Summary
Conference Coverage

Doravirine treatment associated with decreased impact on lipids vs darunavir/ritonavir and low rate of emergent resistance.

Released: July 25, 2018

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

ProCE Banner

Supporters

Janssen

ViiV Healthcare

Partners

AIDS 2018

ProCE Banner

IAS 2018

ProCE Banner